Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
Fiche publication
Date publication
août 2003
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A
Lien Pubmed
Résumé
This randomized, 2 x 2 factorial study compared a semimonthly (LVFU2) with a monthly (FULV) regimen of fluorouracil and leucovorin and 24 versus 36 weeks of each regimen as adjuvant treatment of patients with stage II (Dukes' B2) and III (Dukes' C) colon cancer.
Mots clés
Adenocarcinoma, drug therapy, Adult, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Chemotherapy, Adjuvant, Chi-Square Distribution, Colonic Neoplasms, drug therapy, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil, administration & dosage, Humans, Infusions, Intravenous, Leucovorin, administration & dosage, Male, Middle Aged, Prognosis, Proportional Hazards Models, Survival Analysis, Treatment Outcome
Référence
J. Clin. Oncol.. 2003 Aug;21(15):2896-903